← Back to Search

Elranatamab Access for Multiple Myeloma (MagnetisMM15 Trial)

Phase 4

Recruiting

Research Sponsored by Pfizer

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up a minimum of 90 days after the last dose of study drug

Awards & highlights

MagnetisMM15 Trial Summary

This trial gives MM patients continued access to elranatamab, a drug that has helped them. It's sponsored by Pfizer.

Who is the study for?

This trial is for people with Multiple Myeloma who are benefiting from Elranatamab in ongoing Pfizer studies. They must agree to follow reproductive safety measures and cannot join if they've left the original study or have conditions that increase risk or suicidal thoughts recently.Check my eligibility

What is being tested?

The study provides continued access to Elranatamab, a medication under investigation, for participants who were part of previous trials (Parent Studies) and are still seeing positive effects from the treatment.See study design

What are the potential side effects?

While specific side effects of Elranatamab aren't listed here, similar treatments often cause immune reactions, fatigue, nausea, bone marrow suppression which can lead to infections or bleeding problems.

MagnetisMM15 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ a minimum of 90 days after the last dose of study drug

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~a minimum of 90 days after the last dose of study drug

This trial's timeline: 3 weeks for screening, Varies for treatment, and a minimum of 90 days after the last dose of study drug for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of nonserious adverse events (AEs) leading to permanent discontinuation

Incidence of serious adverse events (SAEs)

MagnetisMM15 Trial Design

1Treatment groups

Experimental Treatment

Group I: ElranatamabExperimental Treatment1 Intervention

Elranatamab is a heterodimeric humanized full length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Elranatamab

2022

N/A

~510

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor

4,570 Previous Clinical Trials

10,915,934 Total Patients Enrolled

35 Trials studying Multiple Myeloma

9,818 Patients Enrolled for Multiple Myeloma

Pfizer CT.gov Call CenterStudy DirectorPfizer

3,476 Previous Clinical Trials

8,092,149 Total Patients Enrolled

25 Trials studying Multiple Myeloma

5,128 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Elranatamab received regulatory clearance by the FDA?

"There is clinical evidence supporting Elranatamab's safety, which has allowed it to receive a score of 3."

Answered by AI

Are there still enrollment opportunities for this investigation?

"Per information listed on clinicaltrials.gov, this pharmaceutical trial is not presently seeking participants. The study was initiated and last updated in September of 2023; however, there are 812 other studies actively recruiting patients at the moment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

2023. "Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06057402.

All > Indianapolis